A comparative analysis of outpatient costs in HIV treatment programs

Flavia Mori Sarti1, Marislei Nishijima, Antonio Carlos Coelho Campino

  • 1Faculdade de Economia, Administração e Contabilidade da Universidade de São Paulo (FEA-USP), São Paulo, SP, Brazil. flamori@usp.br

Revista Da Associacao Medica Brasileira (1992)
|October 24, 2012
PubMed

Insights

The cost of human immunodeficiency virus (HIV) outpatient treatment in Brazil

Area of Science:

  • Health Economics
  • Public Health Policy
  • Infectious Disease Management

Background:

  • Human immunodeficiency virus (HIV) treatment costs vary significantly across healthcare systems.
  • Understanding cost drivers is crucial for efficient resource allocation in public health programs.

Purpose of the Study:

  • To analyze the outpatient treatment costs for HIV in Brazil's public health system, stratified by CD4 cell counts.
  • To compare these costs with those in other national health systems globally.

Main Methods:

  • A retrospective survey of five public HIV outpatient clinics in São Paulo, Brazil.
  • Data collection from medical records for one year of HIV outpatient treatment.
  • Market research and public databases for input prices; literature review for international cost data.

Main Results:

  • The average annual cost of HIV outpatient treatment in Brazil was US$2,572.92 (2006).
  • Costs ranged from US$1,726.19 (CD4 > 500) to US$3,693.28 (51 < CD4 < 200).
  • Antiretrovirals (ARVs) constituted 62% of annual costs; private sector treatment was more expensive internationally.

Conclusions:

  • Key cost drivers include ARVs, other medications, professional services, and diagnostic exams.
  • Health system efficiency influences the magnitude of cost drivers.
  • Findings offer valuable insights for evaluating global HIV treatment programs and informing public policy.
Abstract

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...